Rezolute (RZLT) Return on Capital Employed (2013 - 2026)
Rezolute recorded quarterly Return on Capital Employed of 70.17% in Q1 2026, down 8.6% quarter-over-quarter from 64.62% in Q4 2025, and up 1292.0% year-over-year from 5.04% in Q1 2025.
Rezolute's Return on Capital Employed history runs 14 years deep, the most recent figure standing at 70.17% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1292.0% year-over-year to 70.17%; the TTM figure through Mar 2026 stood at 70.17% (up 1292.0% YoY), while the FY2025 annual figure was 56.18%, up 318.0% from the prior year.
- Return on Capital Employed came in at 70.17% for Q1 2026 at Rezolute, down from 64.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.27% in Q3 2022 to a low of 83.09% in Q1 2025.
- A 5-year average of 56.21% and a median of 59.5% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 4139 bps in 2022 and plunged 3147 bps in 2024, its largest moves.
- Rezolute's Return on Capital Employed stood at 31.79% in 2022, then tumbled by 97 bps to 62.76% in 2023, then decreased by 9 bps to 68.47% in 2024, then rose by 6 bps to 64.62% in 2025, then slipped by 9 bps to 70.17% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 70.17%, 64.62%, and 52.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | -70.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.17% |
| Dec 31, 2025 | -64.62% |
| Sep 30, 2025 | -52.76% |
| Jun 30, 2025 | -64.85% |
| Mar 31, 2025 | -83.09% |
| Dec 31, 2024 | -68.47% |
| Sep 30, 2024 | -59.50% |
| Jun 30, 2024 | -69.98% |
| Mar 31, 2024 | -69.96% |
| Dec 31, 2023 | -62.76% |
| Sep 30, 2023 | -55.49% |
| Jun 30, 2023 | -45.24% |
| Mar 31, 2023 | -38.50% |
| Dec 31, 2022 | -31.79% |
| Sep 30, 2022 | -29.27% |
| Jun 30, 2022 | -38.55% |
| Mar 31, 2022 | -50.52% |
| Dec 31, 2021 | -58.35% |
| Sep 30, 2021 | -70.66% |
| Jun 30, 2021 | -63.94% |
| Mar 31, 2021 | -61.28% |
| Dec 31, 2020 | -94.99% |
| Sep 30, 2020 | -302.79% |
| Jun 30, 2020 | -213.60% |
| Mar 31, 2020 | -142.90% |
| Dec 31, 2019 | -178.18% |
| Sep 30, 2019 | -205.64% |
| Jun 30, 2019 | -473.50% |
| Mar 31, 2019 | -2,549.83% |
| Dec 31, 2018 | 993.27% |
| Sep 30, 2018 | 442.62% |
| Jun 30, 2018 | 1,184.50% |
| Mar 31, 2018 | -1,737.87% |
| Dec 31, 2017 | -414.57% |
| Sep 30, 2017 | -272.47% |
| Jun 30, 2017 | -227.32% |
| Mar 31, 2017 | -215.34% |
| Dec 31, 2016 | -195.71% |
| Sep 30, 2016 | -172.07% |
| Jun 30, 2016 | -184.21% |
| Mar 31, 2016 | -227.04% |
| Dec 31, 2015 | -200.62% |
| Sep 30, 2015 | -142.44% |
| Jun 30, 2015 | -107.47% |
| Mar 31, 2015 | -102.53% |
| Dec 31, 2014 | -149.08% |
| Sep 30, 2014 | -112.92% |
| Jun 30, 2014 | -88.13% |
| Mar 31, 2014 | -294.32% |
| Dec 31, 2013 | 127.42% |
| Sep 30, 2013 | 133.50% |
| Jun 30, 2013 | 155.50% |